Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,902
archived clinical trials in
Irritable Bowel Syndrome (IBS)

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Diagnamics Inc.
mi
from
Encinitas, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Diagnamics Inc.
mi
from
Encinitas, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
MD Studies, Inc.
mi
from
Fountain Valley, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
MD Studies, Inc.
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Paragon Rx Clinical, Inc. - Garden Grove
mi
from
Garden Grove, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Paragon Rx Clinical, Inc. - Garden Grove
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Grossmont Center for Clinical Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Facey Medical Foundation
mi
from
Mission Hills, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Facey Medical Foundation
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Providence Clinical Research
mi
from
North Hollywood, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Providence Clinical Research
mi
from
North Hollywood, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Precision Research Institute, LLC
mi
from
San Diego, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Precision Research Institute, LLC
mi
from
San Diego, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Paragon Rx Clinical, Inc.- Santa Ana
mi
from
Santa Ana, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Paragon Rx Clinical, Inc.- Santa Ana
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
St. Joseph Heritage Healthcare
mi
from
Yorba Linda, CA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
St. Joseph Heritage Healthcare
mi
from
Yorba Linda, CA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Connecticut Clinical Research Institute
mi
from
Bristol, CT
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Connecticut Clinical Research Institute
mi
from
Bristol, CT
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Chase Medical Research, LLC
mi
from
Waterbury, CT
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Palmetto Research
mi
from
Hialeah, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Palmetto Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Nature Coast Clinical Research
mi
from
Inverness, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Nature Coast Clinical Research
mi
from
Inverness, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
The Chappel Group Research
mi
from
Kissimmee, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
The Chappel Group Research
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
San Marcus Research Clinic
mi
from
Miami Lakes, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
San Marcus Research Clinic
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Ocean Blue Medical Research Center, Inc.
mi
from
Miami Springs, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Ocean Blue Medical Research Center, Inc.
mi
from
Miami Springs, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Jesscan Medical Research
mi
from
Miami, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Jesscan Medical Research
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Well Pharma Medical Research Corporation
mi
from
Miami, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Well Pharma Medical Research Corporation
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
New Horizon Research Center
mi
from
Miami, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
New Horizon Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Ormond Medical Arts Pharmaceutical Research Center
mi
from
Ormond Beach, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Ormond Medical Arts Pharmaceutical Research Center
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Meridien Research- Tampa
mi
from
Tampa, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Meridien Research- Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Palm Beach Research Center
mi
from
West Palm Beach, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Palm Beach Research Center
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Research Institute of Central Florida, LLC
mi
from
Winter Park, FL
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Research Institute of Central Florida, LLC
mi
from
Winter Park, FL
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Mount Vernon Clinical Research, LLC
mi
from
Sandy Springs, GA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Mount Vernon Clinical Research, LLC
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Trials Management
mi
from
Metairie, LA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Trials Management
mi
from
Metairie, LA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Delta Research Partners, LLC
mi
from
Monroe, LA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Delta Research Partners, LLC
mi
from
Monroe, LA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Louisiana Research Center, LLC
mi
from
Shreveport, LA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Louisiana Research Center, LLC
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Alan A. Rosen, MD, PA
mi
from
Baltimore, MD
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Alan A. Rosen, MD, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
MedVadis Research Corporation
mi
from
Watertown, MA
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
MedVadis Research Corporation
mi
from
Watertown, MA
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Associates of West Michigan
mi
from
Wyoming, MI
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Associates of West Michigan
mi
from
Wyoming, MI
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
GastroIntestinal Associates
mi
from
Flowood, MS
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
GastroIntestinal Associates
mi
from
Flowood, MS
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
St Louis Center For Clinical Research
mi
from
Saint Louis, MO
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
St Louis Center For Clinical Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Bozeman Health Deaconess Hospital
mi
from
Bozeman, MT
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Bozeman Health Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Nevada
mi
from
Las Vegas, NV
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Healthwise Medical Associates
mi
from
Brooklyn, NY
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Healthwise Medical Associates
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Long Island Gastrointestinal Research Group, LLP
mi
from
Great Neck, NY
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Long Island Gastrointestinal Research Group, LLP
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Carolina Digestive Health Associates
mi
from
Charlotte, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Carolina Digestive Health Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Carolina Digestive Health Associates, PA
mi
from
Concord, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Carolina Digestive Health Associates, PA
mi
from
Concord, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Cumberland Research Associates
mi
from
Fayetteville, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Cumberland Research Associates
mi
from
Fayetteville, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Peters Medical Research
mi
from
HIgh Point, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Peters Medical Research
mi
from
HIgh Point, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Wake Research Associates, LLC
mi
from
Raleigh, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of America - North Carolina, LLC
mi
from
Winston-Salem, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of America - North Carolina, LLC
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Lyndhurst Clinical Research
mi
from
Winston-Salem, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Lyndhurst Clinical Research
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
PMG Research of Winston-Salem
mi
from
Winston-Salem, NC
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
PMG Research of Winston-Salem
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated:  12/31/1969
Lillestol Research LLC
mi
from
Fargo, ND
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide 290 μg Administered Orally for 12 Weeks Followed by a 4-week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation
Status: Enrolling
Updated: 12/31/1969
Lillestol Research LLC
mi
from
Fargo, ND
Click here to add this to my saved trials